Correspondence 0001193125-23-072565 from Q32 Bio Inc. (QTTB)
Q32 Bio Inc.
Date: March 16, 2023 · CIK: 0001661998 · Accession: 0001193125-23-072565
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270414
Letter
HOMOLOGY MEDICINES, INC.
One Patriots Park
Bedford, Massachusetts 01730
March 16, 2023
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 3010
100 F Street, N.E.
Washington, D.C. 20549
Attention: Arzhang Navai
Re: HOMOLOGY MEDICINES, INC.
Registration Statement on Form S-3 (Registration No. 333-270414)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333- 270414) (the “Registration Statement”) of Homology Medicines, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on March 17, 2023, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Peter Handrinos at (617) 948-6060 or Wesley Holmes at (617) 948-6027.
If you have any questions regarding the foregoing, please do not hesitate to contact Peter Handrinos at (617) 948-6060 or Wesley Holmes at (617) 948-6027, of Latham & Watkins LLP. Thank you in advance for your consideration.
Very truly yours,
HOMOLOGY MEDICINES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP HOMOLOGY MEDICINES, INC. One Patriots Park Bedford, Massachusetts 01730 March 16, 2023 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Attention: Arzhang Navai Re: HOMOLOGY MEDICINES, INC. Registration Statement on Form S-3 (Registration No. 333-270414) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333- 270414) (the “Registration Statement”) of Homology Medicines, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on March 17, 2023, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Peter Handrinos at (617) 948-6060 or Wesley Holmes at (617) 948-6027. If you have any questions regarding the foregoing, please do not hesitate to contact Peter Handrinos at (617) 948-6060 or Wesley Holmes at (617) 948-6027, of Latham & Watkins LLP. Thank you in advance for your consideration. Very truly yours, HOMOLOGY MEDICINES, INC. By: /s/ W. Bradford Smith Name: W. Bradford Smith Title: Chief Financial Officer cc: Peter N. Handrinos, Latham & Watkins LLP Wesley C. Holmes, Latham & Watkins LLP